Stem cell therapeutic products* available on the market worldwide									
Product	**Brand/ Company**	**Country**	**Year of release**	**Regulation**	**Condition**	**Cell type**	**Donor type**	**Price (USD approx.)**	**Notes**
ReliNethra	Reliance Life Science	India	2008		eye diseases	limbal stem cells	auto		
CardioRel	Reliance Life Science	India	2010		post acute myocardial infarction	BM MNC/ MSC-rich	auto		
Trinity Evolution	Orthofix	USA		FDA (HTC/P, 21 CFR, part 1271)	orthopedics	Bone matrix with MSC	allo		
Osteocel Plus	NuVasive	USA	2009	FDA (HTC/P, 21 CFR, part 1271)	orthopedics	BM MSC	allo		
AlloStem	AlloSource	USA		FDA (HTC/P, 21 CFR, part 1271)**	orthopedics	BM MSC	allo	3250	
HearticellGram-AMI	FCB PharmiCell	S. Korea	2011	KFDA approved	post acute myocardial infarction	BM MSC	auto	~ 19,000	
Cartistem	Medipost	S. Korea	2012	KFDA approved	degenerative arthritis	Umbilical cord MSC	allo	~ 40,000	
Cupistem	Anterogen	S. Korea	2012	KFDA approved	anal fistula (Chron's disease)	adipose MSC	auto	~ 3,000-5,000	
Prochymal	Osiris Therapeutics	Canada, New Zealand	2012	Health Canada, Medsafe	acute GVHD (pediatric)	BM MSC	allo	~ 200,000 per course, 20k/ dose	
Grafix	Osiris Therapeutics	USA	2011	FDA (HTC/P, 21 CFR, part 1271)	wounds, soft tissue defects	placenta matrix + MSC + other cells	allo		
OvationOS	Osiris Therapeutics	USA	2013	FDA (HTC/P, 21 CFR, part 1271)	bone defects/ orthopedics	bone matrix + MSC + osteoblasts	allo		
Trinity ELITE	Orthofix	USA	2013	FDA (HTC/P, 21 CFR, part 1271)	orthopedics	Bone matrix with MSC and osteoprogenitors	allo		
HiQCell	Regeneus	Australia	2013	TGA medical practitioner exemption	osteoarthriitis, tendonitis	adipose SVF	auto		
map3	RTI Surgical	USA	2014	FDA (HTC/P, 21 CFR, part 1271)	orthopedics	Bone matrix with MAPC	allo		
Holoclar	Chiesi Farmaceutici S.p.A.	Italy/ EU	2015	EMA/ EC approved	eye diseases	limbal stem cells	auto		
Hemacord	NYBC	USA	2011	FDA approved	hematological diseases	hematopoietic stem/ progenitor cells	allo		should be excluded?
4 more cord blood products were approved by FDA, since 2011. They are excluded from analysis									
See FDA notice									
* Stem cell therapeutic product (drug) was defined as it claimed by a company or regulatory agency. The product is authorized for sales and available on the market. The product is approved and/or regulated by federal agency.									
PureGen - FDA notice									